May 25, 2018 11:29 AM ET

Pharmaceuticals

Company Overview of Ritter Pharmaceuticals, Inc.

Company Overview

Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company’s product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuti...

1880 Century Park East

Suite 1000

Los Angeles, CA 90067

United States

Founded in 2004

9 Employees

Phone:

310-203-1000

Fax:

310-919-1600

Key Executives for Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals, Inc. does not have any Key Executives recorded.

Ritter Pharmaceuticals, Inc. Key Developments

Ritter Pharmaceuticals, Inc. Announces Resignation of Jeffrey Benjamin as Vice President, Finance

Ritter Pharmaceuticals, Inc. announced that on and effective as of April 9, 2018, Jeffrey Benjamin resigned as Vice President, Finance of the company. The Company has commenced a search for Mr. Benjamin's replacement and has retained a financial consultant to assist the Company during the transition period until a replacement for Mr. Benjamin is identified.

Ritter Pharmaceuticals, Inc. Amends and Restates Certificate of Incorporation

Ritter Pharmaceuticals, Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-for-10 reverse stock split of the Company’s issued and outstanding common stock, par value $0.001 per share effective March 23, 2018. The Amendment provides that on the Effective Date, every ten shares of the Company’s issued and outstanding Common Stock immediately prior to the Effective Date, shall automatically be reclassified, without any action on the part of the holder thereof, into one share of Common Stock. No fractional shares will be issued as a result of the Reverse Stock Split. Stockholders who otherwise would be entitled to receive a fractional share in connection with the Reverse Stock Split will receive a cash payment in lieu thereof.

Ritter Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Year Ended December 31, 2017

Ritter Pharmaceuticals, Inc. reported earnings results for the fourth quarter and year ended December 31, 2017. For the quarter the company reported net loss attributable to common stockholders of approximately $5.1 million compared to a net loss of approximately $7.6 million for the fourth quarter of 2016. Basic and diluted net loss per share was $0.11 for the three months ended December 31, 2017 compared to basic and diluted net loss per share of $0.74 for the same period in 2016. For the year the company reported a net loss attributable to common stockholders of approximately $11.0 million compared to a net loss of approximately $18.4 million for the year ended December 31, 2016. Basic and diluted net loss per share was approximately $0.50 for the year ended December 31, 2017 compared to basic and diluted net loss per share of approximately $2.04 for the same period in 2016. As of December 31, 2017, company had cash and cash equivalents of approximately $22.6 million.

Similar Private Companies By Industry

Company Name Region
Praetego, Inc. United States
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ritter Pharmaceuticals, Inc., please visit www.ritterpharmaceuticals.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.